TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue…

ENVASARC Trial is Fully Enrolled and Final Data are Expected in Third Quarter 2024 SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals TCON,…

Related Keywords

,Product Development Platform ,Fully Enrolled ,Final Data ,Third Quarter ,News ,Ggregator ,Reaking News ,Uration ,Media ,